2022
Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC.
Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm D, Pusztai L. Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC. Journal Of Clinical Oncology 2022, 40: 516-516. DOI: 10.1200/jco.2022.40.16_suppl.516.Peer-Reviewed Original ResearchImmune-related adverse eventsTriple-negative breast cancerMultivariate logistic regression analysisPD-L1 statusLogistic regression analysisAA raceOverall survivalPathologic responseClinical trialsBreast cancerEarly-stage triple-negative breast cancerIncidence of irAEsPhase I/II trialPathologic complete response rateSignificant associationPhase I/II clinical trialsBaseline body mass indexSafety of immunotherapyWeekly nab-paclitaxelCharlson Comorbidity IndexComplete response ratePrimary efficacy endpointPD-L1 expressionBody mass indexBreast cancer recurrenceAuthor Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
Foldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. Npj Breast Cancer 2022, 8: 17. PMID: 35115541, PMCID: PMC8814070, DOI: 10.1038/s41523-022-00392-3.Peer-Reviewed Original Research
2021
A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC)
Yardley DA, Young RR, Adelson KB, Silber AL, Najera JE, Daniel DB, Peacock N, Finney L, Hoekstra SJ, Shastry M, Hainsworth JD, Burris HA. A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC). Clinical Breast Cancer 2021, 22: 269-278. PMID: 34824002, DOI: 10.1016/j.clbc.2021.10.011.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerCohort 2Cohort 1Breast cancerAndrogen biosynthesisAmylase/lipaseLimited clinical activityPrior chemotherapy regimenPrior chemotherapy regimensMedian treatment durationNausea/vomitingChemotherapy regimenChemotherapy regimensPrimary endpointObjective responseOverall survivalFemale patientsAndrogen receptorClinical activityGrade 3Targetable pathwaysPatientsTherapeutic targetAR modulationTreatment durationNeoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
Foldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. Npj Breast Cancer 2021, 7: 9. PMID: 33558513, PMCID: PMC7870853, DOI: 10.1038/s41523-021-00219-7.Peer-Reviewed Original ResearchStromal tumor-infiltrating lymphocytesWeekly nab-paclitaxelTriple-negative breast cancerPD-L1Nab-paclitaxelAdverse eventsBreast cancerGrade 3/4 treatment-related adverse eventsPhase I/II trialGrade 3/4 adverse eventsTreatment-related adverse eventsDoxorubicin/cyclophosphamidePhase II studyGuillain-Barre syndromeMononuclear inflammatory cellsPathologic complete responseTumor-infiltrating lymphocytesTumor cell stainingEvaluable patientsNeoadjuvant durvalumabSP263 antibodyII trialNeoadjuvant chemotherapyNeoadjuvant therapyPrimary endpointPatterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
Rozenblit M, Mun S, Soulos P, Adelson K, Pusztai L, Mougalian S. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. Breast Cancer Research 2021, 23: 14. PMID: 33514405, PMCID: PMC7844919, DOI: 10.1186/s13058-021-01394-y.Peer-Reviewed Original ResearchConceptsPrior endocrine therapyEndocrine therapyMetastatic breast cancerEffective treatment optionTreatment optionsBreast cancerMedian treatmentMedian OSEE therapyHormone receptor-positive HER2-negative metastatic breast cancerMultivariable Cox proportional hazards regression analysisHER2-negative metastatic breast cancerPrior treatmentCox proportional hazards regression analysisFirst-line therapy initiationProportional hazards regression analysisPrior treatment optionsLines of therapyProportion of patientsKaplan-Meier methodHazards regression analysisPatterns of treatmentElectronic health record-derived dataClinical trial dataOS benefit
2020
Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer
Kunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer. JAMA Network Open 2020, 3: e2027074. PMID: 33226431, PMCID: PMC7684449, DOI: 10.1001/jamanetworkopen.2020.27074.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAdultAgedAnthracyclinesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Agents, PhytogenicBreast NeoplasmsCase-Control StudiesCost-Benefit AnalysisCross-Linking ReagentsDrug Therapy, CombinationFemaleHumansImmunosuppressive AgentsMiddle AgedNeoadjuvant TherapyPaclitaxelQuality-Adjusted Life YearsReceptor, ErbB-2TrastuzumabTubulin ModulatorsUnited StatesConceptsErbB2-positive breast cancerAdjuvant treatment strategiesAdjuvant T-DM1Pathologic complete responseT-DM1Treatment strategiesBreast cancerKATHERINE trialResidual diseaseNeoadjuvant regimenHigher health benefitsHealth care payer perspectiveAdjuvant trastuzumab emtansineAnthracycline/cyclophosphamideDifferent adjuvant therapiesFlatiron Health databaseIncremental cost-effectiveness ratioNeoadjuvant treatment optionsHealth benefitsPositive breast cancerCare payer perspectiveCost-effectiveness ratioBase-case analysisDecision analytic modelH. PatientsPatient and Family Caregiver Considerations When Selecting Early Breast Cancer Treatment: Implications for Clinical Pathway Development
Schulman-Green D, Cherlin E, Capasso R, Mougalian SS, Wang S, Gross CP, Bajaj PS, Eakle K, Patel S, Douglas K, Adelson K. Patient and Family Caregiver Considerations When Selecting Early Breast Cancer Treatment: Implications for Clinical Pathway Development. The Patient - Patient-Centered Outcomes Research 2020, 13: 683-697. PMID: 32508006, DOI: 10.1007/s40271-020-00426-7.Peer-Reviewed Original ResearchConceptsFamily caregiversTreatment optionsDecision regretHealth care system issuesEarly breast cancer treatmentCaregiver considerationsCancer treatment patternsInitial definitive treatmentClinical pathway developmentBreast cancer treatmentFamily caregivers' perspectivesConsideration of patientsDecision pathwaysFindings patientsDefinitive treatmentTreatment patternsSpouse/partnerBreast cancerClinical pathwayTreatment decisionsCancer statusPatientsStage ICaregiver perspectivesTreatment plan
2018
Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database
Chang E, Mougalian SS, Adelson KB, Young MR, Yu JB. Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database. Breast Cancer Research And Treatment 2018, 173: 209-216. PMID: 30242577, DOI: 10.1007/s10549-018-4968-7.Peer-Reviewed Original ResearchConceptsMetastatic-free intervalMetastatic breast cancerInitial breast cancer diagnosisBreast cancer-specific mortalityCancer-specific mortalitySubsequent metastatic diseaseBreast cancer diagnosisMetastatic diseaseFree intervalBreast cancerCancer diagnosisBreast cancer-specific survival ratesMetastatic breast cancer survivalCancer-specific survival ratesDiagnosis of MBCImproved cancer-specific survivalRecurrent metastatic breast cancerCancer-specific survivalEnd Results (SEER) databaseLow tumor gradeBreast cancer survivalChoice of treatmentStratification of patientsMethodsThe SurveillancePurposeThe prevalenceImpact of electronic decision support and targeted educational intervention to increase adherence with ASCO Choosing Wisely breast cancer staging guideline.
Konuthula D, Canavan M, Huntington S, Strait M, Vega T, Framski K, Adelson K. Impact of electronic decision support and targeted educational intervention to increase adherence with ASCO Choosing Wisely breast cancer staging guideline. Journal Of Clinical Oncology 2018, 36: e18826-e18826. DOI: 10.1200/jco.2018.36.15_suppl.e18826.Peer-Reviewed Original Research
2017
Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast Cancer
Mougalian SS, Epstein LN, Jhaveri AP, Han G, Abu-Khalaf M, Hofstatter EW, DiGiovanna MP, Silber ALM, Adelson K, Pusztai L, Gross CP. Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast Cancer. JCO Clinical Cancer Informatics 2017, 1: 1-10. PMID: 30657377, DOI: 10.1200/cci.17.00015.Peer-Reviewed Original ResearchConceptsAdverse effectsEndocrine therapyClinical trialsBreast cancerFrequency of AEsMedication-related adverse effectsTherapy-related adverse effectsBidirectional Text MessagingEndocrine therapy adherenceAdjuvant endocrine therapyMajority of patientsMedical record reviewSevere adverse effectsText message systemConsecutive patientsVaginal symptomsRecord reviewHot flashesTherapy adherenceClinic nursesHistorical controlsPatient acceptanceProvider teamGeneral populationPatientsImpacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making
Dzimitrowicz H, Mougalian S, Storms S, Hurd S, Chagpar AB, Killelea BK, Horowitz NR, Lannin DR, Harigopal M, Hofstatter E, DiGiovanna MP, Adelson KB, Silber A, Abu-Khalaf M, Chung G, Zaheer W, Abdelghany O, Hatzis C, Pusztai L, Sanft TB. Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making. JCO Oncology Practice 2017, 13: jop.2017.022731. PMID: 29048991, DOI: 10.1200/jop.2017.022731.Peer-Reviewed Original ResearchConceptsAdjuvant therapy decisionsRecurrence scoreChemotherapy useRS testingMedical oncologistsHistorical controlsChemotherapy decisionsTherapy decisionsEligibility criteriaNational Comprehensive Cancer Network guidelinesProspective quality improvement projectEarly-stage breast cancerAdjuvant chemotherapy recommendationsTime of diagnosisTime of surgeryQuality improvement projectTesting groupChemotherapy initiationChemotherapy recommendationsMedian timeTrial enrollmentNetwork guidelinesSurgical oncologistsClinical trialsBreast cancerPatient-derived Interstitial Fluids and Predisposition to Aggressive Sporadic Breast Cancer through Collagen Remodeling and Inactivation of p53
Kenny TC, Schmidt H, Adelson K, Hoshida Y, Koh AP, Shah N, Mandeli J, Ting J, Germain D. Patient-derived Interstitial Fluids and Predisposition to Aggressive Sporadic Breast Cancer through Collagen Remodeling and Inactivation of p53. Clinical Cancer Research 2017, 23: 5446-5459. PMID: 28630214, PMCID: PMC5600839, DOI: 10.1158/1078-0432.ccr-17-0342.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBreast NeoplasmsCell Line, TumorCell MovementCell ProliferationCollagenDiagnostic ImagingDisease Models, AnimalDisease SusceptibilityExtracellular FluidFemaleGene Expression ProfilingHeterograftsHumansImmunohistochemistryMiceModels, BiologicalNeoplasm GradingNeoplasm InvasivenessRetrospective StudiesTumor Suppressor Protein p53ConceptsMammary glandBilateral mastectomy patientsInvasion scoreHigh-grade primary tumorsInterstitial fluidNormal mammary glandClin Cancer ResSporadic breast cancerBreast cancer cellsVisceral metastasesSpontaneous tumor formationClinical courseDuctal hyperplasiaResidual diseaseMastectomy patientsPrimary tumorDisease progressionRadiologic examinationBreast cancerLocal invasionMouse modelCollagen depositionMyofibroblast differentiationCancer ResExtracellular matrix
2016
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial
Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona-Calero M, Ma CX, Hershman D, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D. Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial. Npj Breast Cancer 2016, 2: 16037. PMID: 28721390, PMCID: PMC5515340, DOI: 10.1038/npjbcancer.2016.37.Peer-Reviewed Original ResearchProgression-free survivalSelective estrogen receptor downregulatorsMetastatic breast cancerER-positive metastatic breast cancerMedian progression-free survivalArm ABreast cancerArm BHormone receptor-positive metastatic breast cancerRandomized phase II trialPhase II trialEstrogen receptor downregulatorsProteasome inhibitor bortezomibPFS ratesII trialConsortium TrialHazard ratioPostmenopausal womenPreclinical modelsInhibitor bortezomibBortezomibCancerProteasome inhibitorsAdditional evaluationTrialsLactation opposes pappalysin‐1‐driven pregnancy‐associated breast cancer
Takabatake Y, Oxvig C, Nagi C, Adelson K, Jaffer S, Schmidt H, Keely PJ, Eliceiri KW, Mandeli J, Germain D. Lactation opposes pappalysin‐1‐driven pregnancy‐associated breast cancer. EMBO Molecular Medicine 2016, 8: 388-406. PMID: 26951623, PMCID: PMC4818749, DOI: 10.15252/emmm.201606273.Peer-Reviewed Original ResearchConceptsPregnancy-associated breast cancerBreast cancerMammary tumorsDeposition of collagenIGFBP-4Mouse mammary glandIGFBP-5Protective effectEffect of lactationPappalysin-1Expression of inhibitorTransgenic micePAPPPregnancyCancerTransient increaseTumor-associated collagen signaturesMammary glandCollagen signaturesTumorsTransgenic expressionLactationProliferative signalingOncogeneCollagen
2014
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2-positive breast cancer.
Kalinsky K, Chi D, Lee S, Adelson K, Crew K, Chuang E, Makower D, Hershman D, Califano A, Silva J, Maurer M. Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2-positive breast cancer. Journal Of Clinical Oncology 2014, 32: tps666-tps666. DOI: 10.1200/jco.2014.32.15_suppl.tps666.Peer-Reviewed Original Research
2012
Practice patterns in the use of adjuvant therapy for post-menopausal early-stage breast cancer in the pre- and post-Onco type DX era.
Latif A, Small A, Moshier E, Adelson K, Raptis G, Godbold J, Oh W, Galsky M. Practice patterns in the use of adjuvant therapy for post-menopausal early-stage breast cancer in the pre- and post-Onco type DX era. Journal Of Clinical Oncology 2012, 30: e21032-e21032. DOI: 10.1200/jco.2012.30.15_suppl.e21032.Peer-Reviewed Original ResearchAdjuvant therapyOncotype DXHormonal therapyPatient ageStage IPractice patternsEarly-stage breast cancerAdjuvant hormonal therapyNational Cancer DatabaseProportion of patientsUse of chemotherapyBreast cancer patientsLog-binomial regressionBr-CANode negativePrevalence ratiosToxic therapiesCancer patientsPredictive biomarkersCancer DatabaseTreatment utilizationBreast cancerChemotherapyPatientsTherapy
2011
OT3-01-03: Pre-Surgical Evaluation of the AKT Inhibitor MK-2206 in Patients with Operable Invasive Breast Cancer: New York Cancer Consortium Trial P8740.
Kalinsky K, Sparano J, Kim M, Crew K, Maurer M, Taback B, Feldman S, Hibshoosh H, Wiechmann L, Adelson K, Hershman D. OT3-01-03: Pre-Surgical Evaluation of the AKT Inhibitor MK-2206 in Patients with Operable Invasive Breast Cancer: New York Cancer Consortium Trial P8740. Cancer Research 2011, 71: ot3-01-03-ot3-01-03. DOI: 10.1158/0008-5472.sabcs11-ot3-01-03.Peer-Reviewed Original ResearchPre-surgical studyInvasive breast cancerBreast cancerPI3K/AktWeekly MKPost-treatment tissue samplesOperable invasive breast cancerPeripheral blood mononuclear cellsEarly phase clinical studiesDownstream PI3K/Akt pathwayClinical stage IClinical trial programBlood mononuclear cellsMain eligibility criteriaPre-surgical evaluationEarly clinical testingPI3K/Akt pathwayEffects of MKAKT inhibitor MKPost-treatment samplesAnti-cancer propertiesParaffin-embedded tissuesAccrue patientsAnti-cancer agentsNeoadjuvant chemotherapyHormonal Modulation in the Treatment of Breast Cancer
Adelson K, Germain D, Raptis G, Biran N. Hormonal Modulation in the Treatment of Breast Cancer. Endocrinology And Metabolism Clinics Of North America 2011, 40: 519-532. PMID: 21889718, DOI: 10.1016/j.ecl.2011.05.011.Peer-Reviewed Original ResearchPresurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer.
Kalinsky K, Sparano J, Kim M, Crew K, Maurer M, Taback B, Feldman S, Hibshoosh H, Wiechmann L, Adelson K, Hershman D. Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer. Journal Of Clinical Oncology 2011, 29: tps147-tps147. DOI: 10.1200/jco.2011.29.15_suppl.tps147.Peer-Reviewed Original Research
2009
Correlation of Oncotype DX Recurrence Score with Cyclin D1 and ErbB2.
Misra D, Adelson K, Halpern M, Jaffer S, Nagi C, Bleiweiss I, Mandeli J, Raptis G, Germain D. Correlation of Oncotype DX Recurrence Score with Cyclin D1 and ErbB2. Cancer Research 2009, 69: 3035-3035. DOI: 10.1158/0008-5472.sabcs-09-3035.Peer-Reviewed Original ResearchNode-negative breast cancerOncotype DX recurrence scoreOncotype DXRecurrence scoreDX recurrence scoreNegative breast cancerBreast cancerTamoxifen resistanceCyclin D1 overexpressionCyclin D1Cyclin D1 expressionFree survivalOverall survivalEarly-stage node-negative breast cancerColorectal Cancer Study GroupLower relapse-free survivalTamoxifen-resistant breast cancerD1 expressionAdjuvant tamoxifen therapyCancer Study GroupProgression-free survivalUse of chemotherapyResistant breast cancerHigh cyclin D1 expressionHigh recurrence score